Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.

doi:10.1073/pnas.2012294117

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.

Proceedings of the National Academy of Sciences of the United States of America - 27 Oct 2020

Lo Michael K, Albariño César G, Perry Jason K, Chang Silvia, Tchesnokov Egor P, Guerrero Lisa, Chakrabarti Ayan, Shrivastava-Ranjan Punya, Chatterjee Payel, McMullan Laura K, Martin Ross, Jordan Robert, Götte Matthias, Montgomery Joel M, Nichol Stuart T, Flint Mike, Porter Danielle, Spiropoulou Christina F

Abstract excerpt

Remdesivir is a broad-spectrum antiviral nucleotide prodrug that has been clinically evaluated in Ebola virus patients and recently received emergency use authorization (EUA) for treatment of COVID-19. With approvals from the Federal Select Agent Program and the Centers for Disease Control and Prevention's Institutional Biosecurity Board, we characterized the resistance profile of remdesivir by serially passaging...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Monophosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alanine

Share to Betacoronavirus

Share to Drug Tolerance

Share to Ebolavirus

Share to RNA-Dependent RNA Polymerase

Share to SARS-CoV-2

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 33028676
DOI: 10.1073/pnas.2012294117
PMCID: PMC7604432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.PMID 33028676Read ↗

Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitroSemantic proximity Read ↗

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.Semantic proximity Read ↗

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsSemantic proximity Read ↗

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug ResistanceSemantic proximity Read ↗

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms.Semantic proximity Read ↗

Rational Design of the Remdesivir Binding Site in the RNA-dependent RNA Polymerase of SARS-CoV-2: Implications for Potential ResistanceSemantic proximity Read ↗

Remdesivir for the treatment of Covid-19: the value of biochemical studiesSemantic proximity Read ↗

Remdesivir is active in vitro against tick-borne encephalitis virus and selects for resistance mutations in the viral RNA-dependent RNA polymerase.Semantic proximity Read ↗

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.Semantic proximity Read ↗

Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivirSemantic proximity Read ↗

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in miceSemantic proximity Read ↗

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.